Business Wire

AlertEnterprise Looks to Transform Physical Security with Reveal of New Security AI Chatbot Powered by ChatGPT

28.2.2023 17:00:00 EET | Business Wire | Press release

Share

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today revealed the launch of its first-ever Guardian AI Chatbot powered by OpenAI ChatGPT. The company will debut the AI Chatbot globally end of March at the ASIS Europe and ISC West trade events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005630/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine. The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting. (Graphic: Business Wire)

The Guardian AI Chatbot is developed with the world-renowned GPT-3 platform created by OpenAI and is designed to instantly deliver security operators the physical access and security insights that matter most with quick questions and prompts.

“Physical security and access control systems have always contained a tremendous wealth of data but, until now, accessing it was a tedious and manual process,” said Yogesh Ailawadi, SVP Product and Solutions Engineering at AlertEnterprise. “Our Guardian AI Chatbot is poised to redefine the security operator’s experience, increasing their productivity by over 100 times with instant and actionable insights for not only risk mitigation but real business value.”

Mr. Ailawadi noted that the Guardian AI Chatbot is part of the launch of AlertEnterprise’s next-gen AI technology and is completely integrated throughout the Guardian platform.

Get powerful answers in an instant

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine.

The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting.

Some examples are:

  • “Guardian, how many people are on the Trading floor?”
  • “Guardian, how many employees and visitors are in the Data Center?”
  • “Guardian, how many new employee badges did we issue last month?”
  • “Guardian, show me upcoming employee training expirations for restricted area access.”

Drive costs down. Boost employee efficiency.

Using Guardian and its AI Chatbot, CSO and CISO’s can exponentially boost their team’s efficiency by automating tedious tasks and freeing up time to focus on more critical responsibilities. Guardian also leverages a company’s current security investments by connecting to most leading access control vendors and over 200 out-of-the-box connectors to HR, IT and OT systems. And if the organization has a complex mix of access control systems, Guardian connects to and consolidates them all under one platform.

AlertEnterprise founder and CEO Jasvir Gill says there’s no better time for CSO and CISO’s to invest in hyper-efficiency boosting AI platforms like Guardian. “Despite economic headwinds, the world’s most forward-looking CSO and CISO’s are accelerating security digital transformation. With Guardian’s deep forensics and AI data-driven insights, CSO and CISO’s can transform their access control from the stone age to the digital age—making every part of their SOC more automated, expeditious and cost effective, and ultimately the organization more secure. That’s why I view the AlertEnterprise Guardian platform as a deflationary fighting force for companies today.”

To see a live demonstration of the Guardian AI Chatbot, visit AlertEnterprise at Stand C5 at ASIS Europe in Rotterdam, NL, and Booth #13115 at ISC West in Las Vegas, USA.

AlertEnterprise

At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.

AlertEnterprise is committed to using AI in a responsible and ethical manner. We recognize the importance of protecting customer data and safeguarding against potential misuse of AI technology. As such, we have implemented strict policies and procedures to ensure the ethical use of AI and to protect the privacy and security of our customers' data. We believe that transparency and accountability are critical in this regard and remain dedicated to upholding these values throughout our development and operations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release

The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release

Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye